Kevin Charles Gorman is CEO at NEUROCRINE BIOSCIENCES INC (NBIX). They have made 28 open-market trades across 2 companies since 2008, most recently 2026-09-11.
CIK 0001201096
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $1K since 2024, against 27 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| XNCR | SELL · 10b5-1 | 2026-06-15 | 2026-06-17 | $12.31 | $93K | +23.4% | +33.7% | +81.6% |
| NBIX | SELL · 10b5-1 | 2026-05-19 | 2026-05-21 | $154.33 | $37.8M | +5.6% | +3.3% | -0.5% |
| NBIX | SELL · 10b5-1 | 2025-08-07 | 2025-08-11 | $126.41 | $26.9M | +8.8% | +13.6% | +20.6% |
| XNCR | SELL · 10b5-1 | 2025-06-16 | 2025-06-16 | $9.22 | $29K | -8.8% | -1.1% | -4.9% |
| NBIX | SELL · 10b5-1 | 2025-05-27 | 2025-05-29 | $120.38 | $2.3M | +1.9% | +2.6% | +12.8% |
| NBIX | SELL · 10b5-1 | 2025-02-13 | 2025-02-14 | $116.68 | $1.4M | +2.2% | -3.1% | +4.6% |
| NBIX | SELL · 10b5-1 | 2025-02-10 | 2025-02-12 | $118.37 | $538K | -1.2% | -5.6% | -0.4% |
| NBIX | SELL · 10b5-1 | 2025-01-31 | 2025-02-04 | $152.92 | $828K | -24.2% | -25.7% | -27.6% |
| NBIX | SELL · 10b5-1 | 2025-01-27 | 2025-01-29 | $149.46 | $43.7M | -21.8% | -21.9% | -29.4% |
| XNCR | SELL | 2024-09-27 | 2024-10-01 | $20.68 | $110K | +9.1% | +7.7% | +21.5% |
| NBIX | SELL · 10b5-1 | 2024-02-13 | 2024-02-15 | $133.02 | $753K | +0.4% | +3.9% | +5.9% |
| XNCR | BUY | 2024-02-13 | 2024-02-15 | $19.12 | $1K | +7.7% | +5.1% | +0.6% |
| NBIX | SELL · 10b5-1 | 2024-02-06 | 2024-02-08 | $138.74 | $1.5M | -3.0% | +2.9% | +3.2% |
| NBIX | SELL · 10b5-1 | 2024-01-31 | 2024-02-02 | $140.69 | $762K | -6.7% | -5.7% | -1.0% |
| NBIX | SELL · 10b5-1 | 2024-01-08 | 2024-01-10 | $133.02 | $44.7M | +7.1% | +0.9% | +5.9% |
| NBIX | SELL · 10b5-1 | 2023-08-21 | 2023-08-23 | $107.40 | $2.0M | +2.1% | +5.6% | +1.8% |
| NBIX | SELL | 2023-02-06 | 2023-02-08 | $102.90 | $6.0M | -2.5% | -8.5% | -7.2% |
| NBIX | SELL | 2023-01-31 | 2023-02-02 | $110.08 | $596K | -5.8% | -7.8% | -9.8% |
| NBIX | SELL | 2022-02-07 | 2022-02-09 | $80.50 | $1.5M | +10.7% | +12.7% | +3.8% |
| NBIX | SELL | 2021-02-05 | 2021-02-09 | $116.26 | $3.0M | -4.3% | -18.5% | -21.3% |
| NBIX | SELL | 2021-01-08 | 2021-01-12 | $110.22 | $67.9M | +5.9% | +2.3% | -17.7% |
| NBIX | SELL | 2020-11-12 | 2020-11-16 | $90.78 | $615K | +3.1% | +6.5% | +21.3% |
| NBIX | SELL | 2020-08-05 | 2020-08-07 | $118.91 | $806K | -1.6% | -4.5% | -12.7% |
| NBIX | SELL | 2020-04-24 | 2020-04-28 | $99.45 | $578K | +9.0% | +19.8% | +25.5% |
| NBIX | SELL | 2020-02-07 | 2020-02-11 | $103.35 | $671K | -9.5% | -24.4% | +6.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.